- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00678769
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability; and to determine maximum tolerated dose (MTD) of the combination of IMC-A12 (cixutumumab) with temsirolimus in patients with or without biopsiable advanced cancers.
II. To evaluate the biologic effect of each individual drug and this drug combination on expression/phosphorylation of potential markers of response in patients with biopsiable disease.
III. To assess tumor metabolism by positron emission tomography (PET).
SECONDARY OBJECTIVES:
I. To report the clinical tumor response of this combination in a descriptive fashion.
OUTLINE:
DOSE ESCALATION PHASE: Patients receive temsirolimus intravenously (IV) over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After the MTD is determined, subsequent patients are enrolled into the MTD expansion cohort.
MTD EXPANSION COHORT: Patients are assigned to 1 of 3 treatment groups.
GROUP A: Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
GROUP B: Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
GROUP C: Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up within 30 days.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- M D Anderson Cancer Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients with advanced or metastatic cancer
- Patients enrolled in the expansion cohorts may be on antidiabetic treatment, but baseline glucose should be =< 120
- All patients must sign an informed consent indicating that they are aware of the investigational nature of this study; patients must also have signed an authorization for the release of their protected health information
- Patients are allowed to have unlimited prior treatments
- Patients must be registered in the MD Anderson Cancer Center (MDACC) institutional database (CORE) prior to treatment with study drug
- Estimated life expectancy of greater than 3 months
- Patients must be ≥ 4 weeks beyond treatment of any chemotherapy, other investigational therapy, biological, targeted agents or radiotherapy, and must have recovered to =< grade 1 toxicity or previous baseline for each toxicity; exceptions: patients must be >= 6 weeks beyond treatment with monoclonal antibodies; patients may have received palliative low dose radiotherapy to the limbs 1-4 weeks before this therapy provided pelvis, sternum, scapulae, vertebrae, or skull were not included in the radiotherapy field
- Patients must be >= 2 weeks beyond treatment of hormonal therapy
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1
- Absolute neutrophil count >= 1500/mL
- Platelets >= 100,000/mL
- Creatinine =< 2 X upper limit of normal (ULN)
- Total (T.) bilirubin =< 1.5 X ULN
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN
- Women of childbearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test unless prior hysterectomy or menopause (defined as 12 consecutive months without menstrual activity); patients should not become pregnant or breastfeed while on this study; sexually active patients must agree to use contraception prior to study entry, for the duration of study participation, and for 3 months after the last dose
- Patients must be >= 16 years of age; patients with Ewing's Sarcoma must be >= 14 years of age
Exclusion Criteria:
- Patients may not be receiving any other investigational agents
- Patients who are pregnant or breastfeeding
- Patients with history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days
- Patients with uncontrolled intercurrent illness including, but not limited to, active infection requiring hospitalization
- Patients with history of hypersensitivity to monoclonal antibody treatment or immunosuppressant agents
- Patients with history of cerebrovascular accident (CVA), myocardial infarction or unstable angina within the previous six months before starting therapy
- Patients with New York Heart Association class III or greater congestive heart failure or uncontrolled hyperlipidemia (cholesterol > 300 mg/dl; triglyceride 2.5 X ULN despite lipid lowering agent)
- Patients with fasting blood sugar > 120; patients who are on oral hypoglycemic agents and insulin will be excluded; exception: patients in the expansion cohorts may be on antidiabetic treatment (including hypoglycemic agents and/or insulin) if controlled
- Patients on drugs that are strong P450 cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers; these drugs should be stopped 5 half-lives prior to starting investigational agents with temsirolimus; the strong inducing or inhibiting agents should not restart until 1 week after the end of study treatment; the principal investigator (PI) or his designee will go over/check the list of medication for individual patients; NOTE: Physiologic replacement of steroids (with either prednisone or hydrocortisone) in patients with adrenalectomy will be allowed
- Patients with history of brain metastasis are eligible, however the brain metastases should have been treated (treatment defined as surgery or radiation therapy [RT]) and the patient should have been free from symptoms/signs and off steroids for at least 3 months before study entry
- Patients with highly aggressive lymphoma (i.e. Burkitt's)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Group A (temsirolimus on days 15 and 22 course 1)
Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses.
Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
|
Badania korelacyjne
Badania korelacyjne
Biorąc pod uwagę IV
Inne nazwy:
Given IV
Inne nazwy:
|
Eksperymentalny: Group B (cixutumumab on days 15 and 22 of course 1)
Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses.
Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
|
Badania korelacyjne
Badania korelacyjne
Biorąc pod uwagę IV
Inne nazwy:
Given IV
Inne nazwy:
|
Eksperymentalny: Group C (temsirolimus on days 1, 8, 15, and 22)
Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
|
Badania korelacyjne
Badania korelacyjne
Biorąc pod uwagę IV
Inne nazwy:
Given IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change in phosphorylation levels of other biomarkers before and after treatment
Ramy czasowe: Baseline to up to day 11
|
Other markers include: insulin-like growth factor 1 receptor (IGF-1R), phosphorylated (p)IGF-1R, insulin receptor substrate-1 (IRS-1), phosphatase and tensin homolog gene (PTEN), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and cluster of differentiation (CD)31.
Generalized Estimating Equations model will be used to model the correlated IHC score between treatment arms.
|
Baseline to up to day 11
|
Change in phosphorylation levels of v-akt murine thymoma viral oncogene homolog 1 in terms of difference in IHC score
Ramy czasowe: Baseline to up to day 11
|
Generalized Estimating Equations model will be used to model the correlated IHC score between treatment arms.
|
Baseline to up to day 11
|
MTD of combination of cixutumumab and temsirolimus defined as the highest dose level at which no more than 1 of 6 evaluable patients has had a dose-limiting toxicity
Ramy czasowe: 28 days
|
28 days
|
|
Tumor metabolism as assessed by PET scan before and after treatment
Ramy czasowe: Baseline to up to day 28 of course 2
|
The PET standardized uptake value (SUV) of all patients will be pooled together to plot the overall trend of PET SUV over time, the percent change in PET SUV will be estimated and 95% confidence intervals will be provided.
|
Baseline to up to day 28 of course 2
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Tumor response rate defined as CR + PR assessed by Response Evaluation Criteria in Solid Tumors and CHESON criteria
Ramy czasowe: Up to 30 days after completion of study treatment
|
Up to 30 days after completion of study treatment
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Aung Naing, M.D. Anderson Cancer Center
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- NCI-2009-00282 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- P30CA016672 (Grant/umowa NIH USA)
- U01CA062461 (Grant/umowa NIH USA)
- U01CA062487 (Grant/umowa NIH USA)
- CDR0000595388
- 2007-0595 (Inny identyfikator: M D Anderson Cancer Center)
- 8109 (Inny identyfikator: CTEP)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Laboratoryjna analiza biomarkerów
-
US Department of Veterans AffairsZakończonyZaburzenia językowe | Afazja | Zaburzenia mowyStany Zjednoczone
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Jeszcze nie rekrutacjaZakażenia wirusem HIV | Zapalenie wątroby typu B
-
Seoul National University HospitalNieznanyChoroba Alzheimera | Łagodne upośledzenie funkcji poznawczychRepublika Korei
-
Vanderbilt University Medical Center4DMedicalZakończonyZaciskające zapalenie oskrzelikówStany Zjednoczone
-
St. Antonius HospitalRoche DiagnosticsRekrutacyjnyJakość życia | Powikłania pooperacyjne | ŚmierćHolandia
-
Chinese PLA General HospitalRekrutacyjny
-
Cairo UniversityOlfat ShakerZakończonyPorównanie poziomów paksyliny w ślinie u OPML i OSCC u osób zdrowychEgipt
-
Protgen LtdNieznany
-
Beni-Suef UniversityZakończonyPosocznica | MoralnośćEgipt